Headache and Migraine

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 1, 2022.

In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]

The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

Bradford C. Sippy, the chief executive officer of Tremeau Pharmaceuticals, spoke about the company’s work to reformulate rofecoxib, known now as TRM-201, to treat acute migraine.

Originally approved for the preventive treatment of episodic migraine in Sept 2021, atogepant’s potential new indication stems from positive results from the double-blind, placebo-controlled, phase 3 PROGRESS trial.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.

On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.

Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.

Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.

Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.

The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.

The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]

A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.

The most common adverse events reported by individuals using the dihydroergotamine nasal powder were nasal discomfort, dysgeusia, and nasal congestion, all of which were mild and transient in nature.

Secondary outcomes, assessed by the change in the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies.

The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.